• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Cardlytics Inc.

    1/5/26 4:23:23 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001941467
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Cardlytics, Inc.
    SEC File Number
    001-38386
    Address of Issuer
    675 PONCE DE LEON AVENUE, NE
    SUITE 4100
    ATLANTA
    GEORGIA
    30308
    Phone
    888-798-5802
    Name of Person for Whose Account the Securities are To Be Sold
    Lynton Nicholas Hollmeyer
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    62537317.895405654801/05/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/31/2025Restricted Stock VestingIssuerCheckbox not checked625312/31/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    01/05/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Nicholas H. Lynton

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CDLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer converted options into 12,788 shares and sold $7,316 worth of shares (6,253 units at $1.17), increasing direct ownership by 6% to 122,862 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/5/26 6:56:15 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Chief Executive Officer Gupta Amit converted options into 14,349 shares and sold $6,794 worth of shares (5,807 units at $1.17), increasing direct ownership by 2% to 506,852 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/5/26 6:53:23 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Chief Financial Officer Desieno Alexis converted options into 14,349 shares and sold $10,070 worth of shares (8,607 units at $1.17), increasing direct ownership by 3% to 201,159 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/5/26 6:47:13 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    SEC Filings

    View All

    SEC Form 144 filed by Cardlytics Inc.

    144 - Cardlytics, Inc. (0001666071) (Subject)

    1/5/26 4:23:23 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    12/18/25 8:00:14 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    12/5/25 8:04:20 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Third Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the third quarter ended September 30, 2025. "In Q3, we've taken decisive action that we believe will reset our business, improve our financial health, and set ourselves on a viable path to return to growth," said Amit Gupta, CEO of Cardlytics. "We are moving forward with sharper focus and discipline, prioritizing initiatives that build on our fundamental strengths and where we believe we can win. Our mandate is clear – continue to deliver for our partners and advertisers, strengthen what differentiates us, and unlock long-term value for our shareholders." Third Quarter 2025 Financial Results

    11/5/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its Third Quarter 2025 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the third quarter ending September 30, 2025 will be released on November 5, 2025, after market close. Conference Call Details: When: November 5, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 18219. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party

    10/22/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Evercore ISI initiated coverage on Cardlytics with a new price target

    Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

    10/11/24 8:36:58 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by Northland Capital with a new price target

    Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

    8/16/24 8:54:02 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

    8/15/24 7:18:52 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:46:37 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:45:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:39:19 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

    Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

    4/30/25 9:00:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    $CDLX
    Financials

    Live finance-specific insights

    View All

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Cardlytics Announces Third Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the third quarter ended September 30, 2025. "In Q3, we've taken decisive action that we believe will reset our business, improve our financial health, and set ourselves on a viable path to return to growth," said Amit Gupta, CEO of Cardlytics. "We are moving forward with sharper focus and discipline, prioritizing initiatives that build on our fundamental strengths and where we believe we can win. Our mandate is clear – continue to deliver for our partners and advertisers, strengthen what differentiates us, and unlock long-term value for our shareholders." Third Quarter 2025 Financial Results

    11/5/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its Third Quarter 2025 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the third quarter ending September 30, 2025 will be released on November 5, 2025, after market close. Conference Call Details: When: November 5, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 18219. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party

    10/22/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Second Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the second quarter ended June 30, 2025. "Building on the progress we've made over the past year, we are navigating headwinds by doubling down on our diversification efforts and reinforcing our unique network capabilities," said Amit Gupta, CEO of Cardlytics. "We believe our strategic shifts will position us for long-term profitable growth and enable us to deliver on the promise to our stakeholders." Second Quarter 2025 Financial Results Revenue was $63.2 million, a decrease of 9% year-over-year compared to $69.6 million in the second quarter of 2024. Billings, a non-GAAP metric, was $1

    8/6/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    7/2/24 7:05:14 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/29/24 5:05:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/18/24 7:46:57 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology